Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363630 | 0.87 | AKR1C3 (0.43) | AKR1C3LMNANSD2L3MBTL1ALDH1A1 | |
| SCHEMBL2033939 | 0.83 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL14940417 | 0.81 | ALDH1A3 (0.45) | LMNAL3MBTL1ALDH1A1MAPTALOX15 | |
| SCHEMBL188362 | 0.80 | ADRA2C (0.42) | LMNAL3MBTL1ALDH1A1MAPTKDM4E | |
| SCHEMBL2125041 | 0.80 | MAPT (0.50) | AKR1C3LMNAALDH1A1HSD17B10MAPT | |
| SCHEMBL26610433 | 0.79 | MAPT (0.45) | LMNAL3MBTL1ALDH1A1HSD17B10MAPT | |
| SCHEMBL6199111 | 0.79 | LGMN (0.49) | LMNAL3MBTL1ALDH1A1HSD17B10MAPT | |
| SCHEMBL1570389 | 0.79 | HPGD (0.51) | LMNAL3MBTL1ALDH1A1HSD17B10MAPT | |
| SCHEMBL1814799 | 0.79 | ADRB1 (0.58) | — | |
| SCHEMBL2481232 | 0.78 | AKR1C3 (0.46) | AKR1C3ALDH1A1HSD17B10MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157848-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | Nanjing Ruijie Pharma Co., Ltd. (CN) | 2023-04-05 | — | — | EP | claimed |
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| CN-107250116-A | 3,5 diamino-pyrazole kinase inhibitors | 埃克希金医药品有限公司 | 2017-10-13 | — | — | CN | claimed |
| US-9730914-B2 | 3,5-diaminopyrazole kinase inhibitors | Axikin Pharmaceuticals (US) | 2017-08-15 | — | — | US | claimed |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | claimed |
| US-9546163-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| WO-2016106309-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | claimed |
| EP-4157848-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | Nanjing Ruijie Pharma Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
| CN-107250116-B | 3, 5-diaminopyrazole kinase inhibitors | 艾士盟医疗公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3237407-B1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | SMA THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-108117551-B | Substituted (1H-pyrazolo [3,4-b ] pyridine) urea compound and anti-tumor application thereof | 华东理工大学 | 2020-03-27 | — | — | CN | disclosed |
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| CN-107250116-A | 3,5 diamino-pyrazole kinase inhibitors | 埃克希金医药品有限公司 | 2017-10-13 | — | — | CN | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2010067886-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | AKR1C3 2082/4885LMNA 2416/4885NSD2 4492/4885 |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | AKR1C3 2082/4885LMNA 2416/4885NSD2 4492/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | AKR1C3 427/4885LMNA 3734/4885NSD2 1990/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | AKR1C3 427/4885LMNA 3734/4885NSD2 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.